Page 3 - Array Biopharma News Today

BioLoomics Inc., a Boulder-based life-sciences startup, has raised $8.7 million in seed financing.

SAN FRANCISCO--(BUSINESS WIRE)--Character Biosciences, a drug discovery and development company leveraging human genetics and medical imaging-based machine learning to target disease progression, today announced the appointment of Laura Carter, Ph.D. as Chief Scientific Officer. Dr. Carter brings a track record of m...

The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

/PRNewswire/ -- Dr. Marvin H. Caruthers of the University of Colorado, Boulder, has won the inaugural Richard N. Merkin Prize in Biomedical Technology for...

Dilated Cardiomyopathy market report gives details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry in this market research report. The re...

The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.

/PRNewswire/ -- The "Gastric Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.coms offering. This report provides...

A company providing a single platform to support clients’ clinical trial journeys has closed a $3 million Series A funding.

ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Rating) and Regulus Therapeutics (NASDAQ:RGLS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Volatility & Risk ASLAN Pharmaceuticals has a beta of […]